Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data for ...

Not too long ago, racers were sneaking nitrous bottles into their trunks like teenagers hiding contraband. Today, the go-fast game is less about stuffing extra oxygen in and more about deleting the ...

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial ...

Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, ...